Lucigen Sells To LGC
BroadOak Partners advises Lucigen Corporation on the sale of the company to LGC Limited. Lucigen is a leading provider of molecular biology enzymes, reagents, and kits for high growth applications in clinical diagnostics, drug discovery, synthetic biology, and gene editing. The full press release is below. LGC acquires Lucigen, strengthening its reagents offering to the […]